Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT05729048

Starling/CRRT Observational Study

Starling Continuous Renal Replacement Therapy (CRRT) Observational Study

Status
Withdrawn
Phase
Study type
Observational
Enrollment
0 (actual)
Sponsor
Baxter Healthcare Corporation · Industry
Sex
All
Age
18 Years – 95 Years
Healthy volunteers
Not accepted

Summary

Hemodynamic optimization of critically ill patients is a goal for clinicians in order to afford the patient the best possible outcomes. Being able to precisely and rapidly determine patient fluid responsiveness provides the bedside physician and nursing staff the information needed to make critical decisions in regard to the patient's fluid status and management of additional fluids and medications. As fluid management and cardiac output determination are linked to better decision-making and improved outcomes in ICU, the use of a dynamic assessment of fluid responsiveness becomes a key tool for patient management. This study is designed to collect treatment and outcome data on patients that have undergone hemodynamic monitoring during CRRT therapy.

Conditions

Interventions

TypeNameDescription
DEVICEStarlingStarling is a portable, non-invasive, cardiac output detector system. The Starling monitor measures the cardiac output by employing electrical bioreactance. Bioreactance is a measure of the electrical characteristics of a volume of tissue and fluid. In the case of cardiac output measurements, the relevant tissue includes the heart and the immediate surrounding volume of the thorax. The relevant fluid is blood. The Starling electrode is a double electrode sensor. Within each sensor, one electrode is used to transmit a high frequency sine wave into the body, while the resulting voltage is measured at the adjacent electrode. This information is used to determine cardiac output. The Starling monitor also measures and displays associated hemodynamic parameters based on calculations of measurements already incorporated into the Starling monitor.

Timeline

Start date
2023-07-15
Primary completion
2025-03-14
Completion
2025-03-14
First posted
2023-02-15
Last updated
2023-07-14

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT05729048. Inclusion in this directory is not an endorsement.